Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.
The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.
First of three Phase III studies of Taltz in ankylosing spondylitis is positive, using a high bar for primary endpoint efficacy. But Novartis' Cosentyx, already approved in this indication, is expected to dominate the market.
National Cancer Institute's Phase II combo data for AstraZeneca's PARP inhibitor Lynparza and PD-L1 inhibitor Imfinzi are encouraging, but more research is needed to show a role for immunotherapy combinations in advanced prostate cancer.
Phase III data at ASCO GU meeting impress, but raise questions about safety in new non-metastatic CRPC indication – rash, fractures and falls for Erleada (apalutamide) and unexplained deaths after termination of treatment for Xtandi (enzalutamide).